Steven Davenport1. 1. Pardee RAND Graduate School, 1776 Main St, Santa Monica, CA, USA. Electronic address: stevenseandavenport@gmail.com.
Abstract
BACKGROUND: Ten U.S. states, Canada, and Uruguay have passed laws to legalize the production and sale of cannabis for non-medical purposes. Available research has documented rapidly falling prices and changing product mixes, but many details are not well understood: particularly, the popularity, prices, and product characteristics of different cannabis edibles and extract-based products - each offering different ways to consume cannabis, with unclear health consequences. METHODS: This paper analyzes data from Washington's recreational cannabis market, which has recorded over 110 million retail item-transactions from July 2014 to October 2017. Previous research on price and product trends has focused mostly on herbal cannabis, which accounts for the majority, but a decreasing share, of sales. This paper applies advanced text-analytic methods to provide new insights, including (A) estimating potency data for edibles and (B) identifying extract sub-types. Patterns and trends are described, across product types, regarding THC and CBD profiles and price per THC. RESULTS: Extracts accounted for 28.5% of sales in October 2017. Of extracts categorized to subtype, nearly half were identified as "dabs", and another half "cartridges". In October 2017, price per 10 mg THC was roughly $3 among edibles, 70 cents among extract cartridges, and 30-40 cents for other flower and other extracts; solid concentrates offered the lowest priced THC among extract products. Price declines continue but have slowed. High-CBD chemovars are becoming more common, but still are almost non-existent in flower marijuana and rare (1% of sales) among extract products. CONCLUSION: As Washington's recreational cannabis market has developed over three and a half years, trends identified in that market may serve as an early indication of potential issues in other states. Legislators and regulators in other jurisdictions with commercial non-medical cannabis markets may wish to establish policies responsive to these trends in product popularity, price, and potency.
BACKGROUND: Ten U.S. states, Canada, and Uruguay have passed laws to legalize the production and sale of cannabis for non-medical purposes. Available research has documented rapidly falling prices and changing product mixes, but many details are not well understood: particularly, the popularity, prices, and product characteristics of different cannabis edibles and extract-based products - each offering different ways to consume cannabis, with unclear health consequences. METHODS: This paper analyzes data from Washington's recreational cannabis market, which has recorded over 110 million retail item-transactions from July 2014 to October 2017. Previous research on price and product trends has focused mostly on herbal cannabis, which accounts for the majority, but a decreasing share, of sales. This paper applies advanced text-analytic methods to provide new insights, including (A) estimating potency data for edibles and (B) identifying extract sub-types. Patterns and trends are described, across product types, regarding THC and CBD profiles and price per THC. RESULTS: Extracts accounted for 28.5% of sales in October 2017. Of extracts categorized to subtype, nearly half were identified as "dabs", and another half "cartridges". In October 2017, price per 10 mg THC was roughly $3 among edibles, 70 cents among extract cartridges, and 30-40 cents for other flower and other extracts; solid concentrates offered the lowest priced THC among extract products. Price declines continue but have slowed. High-CBD chemovars are becoming more common, but still are almost non-existent in flower marijuana and rare (1% of sales) among extract products. CONCLUSION: As Washington's recreational cannabis market has developed over three and a half years, trends identified in that market may serve as an early indication of potential issues in other states. Legislators and regulators in other jurisdictions with commercial non-medical cannabis markets may wish to establish policies responsive to these trends in product popularity, price, and potency.
Authors: Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller Journal: JAMA Date: 2015 Jun 23-30 Impact factor: 56.272
Authors: Peggy van der Pol; Nienke Liebregts; Ron de Graaf; Dirk J Korf; Wim van den Brink; Margriet van Laar Journal: Drug Alcohol Depend Date: 2013-07-22 Impact factor: 4.492
Authors: Vincent Varlet; Nicolas Concha-Lozano; Aurélie Berthet; Grégory Plateel; Bernard Favrat; Mariangela De Cesare; Estelle Lauer; Marc Augsburger; Aurélien Thomas; Christian Giroud Journal: Sci Rep Date: 2016-05-26 Impact factor: 4.379
Authors: George Sam Wang; Christine Buttorff; Asa Wilks; Daniel Schwam; Gregory Tung; Rosalie Liccardo Pacula Journal: Int J Drug Policy Date: 2022-04-22
Authors: Rosalie Liccardo Pacula; Jason G Blanchette; Marlene C Lira; Rosanna Smart; Timothy S Naimi Journal: Am J Prev Med Date: 2021-02-12 Impact factor: 5.043
Authors: Sarah L Withey; Brian D Kangas; Sophia Charles; Andrew B Gumbert; Jessica E Eisold; Susan R George; Jack Bergman; Bertha K Madras Journal: Drug Alcohol Depend Date: 2021-02-17 Impact factor: 4.492
Authors: Howard Padwa; David Huang; Larissa Mooney; Christine E Grella; Darren Urada; Douglas S Bell; Brittany Bass; Anne E Boustead Journal: Subst Abuse Treat Prev Policy Date: 2022-05-08
Authors: MaryBeth Dobbins; Mannat Rakkar; Katharine Cunnane; Sarah D Pennypacker; Kimberly G Wagoner; Beth A Reboussin; E Alfonso Romero-Sandoval Journal: Front Public Health Date: 2022-06-17